

## GENERAL INFORMATION

### CONGRESS VENUE

Grand Hotel 4 opatijska cvijeta, V. C. Emina 6, Opatija

**Registration desk:** Ground floor

**Speakers' Ready Room:** Ground floor

### Congress Halls

Ground floor: Lavander Hall

1<sup>st</sup> floor: Orchid Hall

2<sup>nd</sup> floor: Mimosa Hall

**Poster display:** 2<sup>nd</sup> floor

**Exhibitions:** 2<sup>nd</sup> floor

### REGISTRATION

#### *Registration Desk*

##### **Available services**

- Registration and payment
- Technical assistance (oral and poster presentations)
- Information
- Certificates
- Credits (Croatian participants only)

##### **Opening hours**

September 15<sup>th</sup> 12:00 – 19:30

September 16<sup>th</sup> 8:30 – 19:00

September 17<sup>th</sup> 8:30 – 16:00

September 18<sup>th</sup> 8:30 – 13:30

Only registered members may take part in the scientific sessions and attend the social events offered by the Congress.

#### *Payment and Registration Fees*

	<b>Before June 15, 2010</b>	<b>After June 15, 2010</b>
<b>Croatian Pharmacological Society (CPS) Members</b>	1.100,00 kn	1.300,00 kn
<b>Other Participants</b>	1.400,00 kn	1.600,00 kn
<b>Students</b>	350,00 kn	400,00 kn
<b>Accompanying Persons</b>	450,00 kn	500,00 kn

The Congress fee for the CPS members, other participants and students includes:

- Participation in the scientific program and promotional activities
- Abstract Book and Congress materials
- Welcome Cocktail
- Refreshments during coffee breaks
- Excursion to Istria
- Gala Dinner

The Congress fee for the accompanying persons includes:

- Welcome Cocktail
- Excursion to Istria
- Gala Dinner

**Payment:** cash (no credit card and check payments acceptable)

### **BADGES**

The official Congress badge must be worn for admission to all Congress activities.

### **OFFICIAL LANGUAGES**

Croatian and English

### **ORAL PRESENTATIONS**

- A Speakers' Ready Room will be available for speakers every day through the Congress.
- Technical assistants will be at disposal during specified periods of plenary lectures and symposia sessions.
- Presentations should be handed to the technical assistants 60 minutes before the start of plenary lectures and symposia.
- Every effort must be made to keep strictly to the time-table of the scientific sessions. Chairpersons are asked to interrupt speakers if they exceed the periods of their presentations.

### **POSTER PRESENTATIONS**

- Poster number corresponding to the authors abstract will already be posted at the top of the board.
- Poster mounting: 8:00 – 9:00
- Presenting authors are requested to be present at their posters during the Poster session for which their poster has been scheduled. At that time posters' chairpersons will be present and discuss posters.
- Poster removal: at the conclusion of the Poster sessions.

### **INSTRUCTIONS FOR *IN EXTENSO* MANUSCRIPTS SUBMISSION**

Selected *in extenso* manuscripts will be published in a special issue of *Periodicum Biologorum*. Instructions for authors are on the web page: <http://biologorum.irb.hr>. Manuscripts should be submitted in electronic form until October 1, 2010.

## **CERTIFICATES AND CREDITS**

Certificates of attendance, certificates for invited lectures and/or credits of the Croatian Chamber of Medical Doctors, will be issued at the Registration desk only to registered participants, upon request.

## **SOCIAL PROGRAMME**

### **Wednesday, September 15<sup>th</sup>**

19:30 – 22:00 Opening Ceremony and Welcome Cocktail, Grand Hotel 4 opatijska cvijeta

### **Friday, September 17<sup>th</sup>**

16:30 – Excursion to Istria

21:00 – Gala Dinner, Grand Hotel 4 opatijska cvijeta

### **Saturday, September 18<sup>th</sup>**

14:30 – Boat Excursion (it will only be organized if there are enough attendees. Not included in the Congress fee.)

## **PROGRAMME OVERVIEW**

### ***SEPTEMBER 15 (WEDNESDAY)***

*12:00 – 19:30 Registration*

**19:30 – 22:00 OPENING CEREMONY, WELCOME COCKTAIL**

### ***SEPTEMBER 16 (THURSDAY)***

*08:30 – 19:00 Registration*

**09:00 – 10:00 PLENARY LECTURE**

**Orchid Hall**

Pharmacological research in Europe: A bid for the 21<sup>st</sup> Century

*10:00 – 10:30 Coffee break*

**10:30 – 12:30 SYMPOSIA, HALMED-INFO-DAY**

**Mimosa Hall**

Imaging approaches and model systems to study disease pathology and pharmacology

**Lavender Hall**

Molecular basis and treatment of behavioral and emotional disorders in children, adolescents and adults

**Orchid Hall**

HALMED-Info-Day

*12:30 – 14:00 Lunch*

**14:00 – 15:00 PLENARY LECTURE**

**Orchid Hall**

Neuronal potassium channels: Novel targets for analgesia and neuroprotection

**15:00 – 17:00 SYMPOSIA, HALMED-INFO-DAY**

**Mimosa Hall**

Molecular mechanisms of diseases and future therapies

**Lavender Hall**

Molecular basis and treatment of Alzheimer's disease

**Orchid Hall**

HALMED-Info-Day

**17:00 – 18:00 POSTER SESSION 1**

**18:00 – 19:00 ANNUAL ASSEMBLY OF THE CROATIAN  
PHARMACOLOGICAL SOCIETY, Orchid Hall**

***SEPTEMBER 17 (FRIDAY)***

*08:30 – 16:00 Registration*

**09:00 – 10:00 PLENARY LECTURE**

**Orchid Hall**

The endothelial saga

*10:00 – 10:30 Coffee break*

**10:30 – 12:30 SYMPOSIA, WORKSHOP**

**Mimosa Hall**

Experimental central nervous system damage: Mechanisms and therapy

**Lavender Hall**

Pharmacological aspects of selected functional foods and its constituents

**Orchid Hall**

Workshop for responsible persons in pharmacovigilance: 'What did the new Rule book bring?'

*12:30 – 14:00 Lunch*

**14:00 – 15:00 PLENARY LECTURE**

**Orchid Hall**

The validation of protein targets for drug discovery

**15:00 – 16:00 POSTER SESSION 2**

***SEPTEMBER 18 (SATURDAY)***

***08:30 – 13:30 Registration***

**09:00 – 11:00 SYMPOSIA, WORKSHOP**

**Mimosa Hall**

Clinical pharmacology: From drug development to drug prescribing

**Lavender Hall**

Nephropharmacology

**Orchid Hall**

Workshop for responsible persons in pharmacovigilance: ‘What did the new Rule book bring?’

***11:00 – 11:30 Coffee break***

**11:30 – 13:30 SYMPOSIUM, ROUND TABLE, WORKSHOP**

**Mimosa Hall**

Pharmacogenomics

**Lavender Hall**

Compliance - A nightmare or a useful tool

**Orchid Hall**

Workshop for responsible persons in pharmacovigilance: ‘What did the new Rule book bring?’

**13:30 CLOSING CEREMONY**

## **PROGRAMME**

## **SEPTEMBER 15 (WEDNESDAY)**

**12:00 – 19:30 Registration**

**19:30 – 22:00 Opening Ceremony, Welcome Cocktail**

## **SEPTEMBER 16 (THURSDAY)**

**09:00 – 10:00 PLENARY LECTURE (Orchid Hall)**

**PL1. Moilanen E:** Pharmacological research in Europe: A bid for the 21<sup>st</sup> Century

**10:30 – 12:30 Symposium 1 (S1), Mimosa Hall  
Symposium 2 (S2), Lavender Hall  
HALMED-Info-Day (H1, H2, H3), Orchid Hall**

**S1 IMAGING APPROACHES AND MODEL SYSTEMS TO STUDY DISEASE PATHOLOGY AND PHARMACOLOGY** (*Organizer: Križ J; Chairpersons: Križ J, Mück-Šeler D*)

S1.1. **Julien JP:** Imaging the distribution and therapeutic effect of antibody against misfolded SOD1 in ALS mice

S1.2. **Maysinger D:** Nanoparticles for cell imaging and drug delivery

S1.3. **Koop R:** Optical imaging applications to study disease pathology and pharmacology *in vivo*

S1.4. **Križ J:** Development of model system for real time imaging of brain responses to injury and therapies

**S2 MOLECULAR BASIS AND TREATMENT OF BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN, ADOLESCENTS AND ADULTS**

(*Organizer: Pivac N; Chairpersons: Pivac N, Borovečki F*)

S2.1. **Pivac N,** Nikolac M, Nedić G, Dodig-Ćurković M, Ćurković M, Škledar M, Mück-Šeler D: Molecular markers of behavioral and emotional disorders

S2.2. **Harro J,** Reif A, Merenäkk L, Hiio K, Kurrikoff T, Heterich S, Kiive E, Loit HM, Tulviste T, Veidebaum T, Lesch KP: Genetic predisposition to drug use and psychiatric vulnerability in general population

S2.3. **Dodig-Ćurković K,** Boričević Maršanić V, Ćurković M, Delalle M, Filipović G: Diagnostic criteria and treatment of behavioral disorders in children and adolescents

S2.4. **Nedić G,** Hercigonja-Novković V, Dodig-Ćurković K, Ćurković M, Škledar M, Nikolac M, Mück-Šeler D, Pivac N: Dopaminergic mechanisms in attention deficit hyperactivity disorders in children

S2.5. **Boričević Maršanić V,** Dodig-Ćurković K, Grgić N, Juretić Z: Treatment of emotional disorders in children and adolescents

**H1. Tomić S: HALMED – SEVEN YEARS OF EXPERIENCE**

## **H2 REGISTRATION OF DRUGS** (*Moderator: Tomić S*)

H2.1. **Šimpraga B**: New collaboration agreement between drug regulatory authorities in European Union associated countries (nCADREAC)

H2.2. **Čogelja-Čajo G**: Non-clinical drug assessment

H2.3. **Ikić Komesar J**, Uzeirbegović S, Tomić S: Variation system in Croatia

H2.4. **Milčić N**: The work of the Medicinal Products Committee of the Agency for Medicinal Products and Medical Devices

## **H3 PHARMACEUTICAL CONTROL OF QUALITY** (*Moderator: Truban Žulj R*)

H3.1. **Truban Žulj R**, Plazonić A, Tomić S: Medicinal products quality control and deficiency monitoring in the Agency for Medicinal Products and Medical Devices

H3.2. **Mandušić Nazor T**, Pipić-Kosanović M, Truban Žulj R, Tomić S: Special quality control of vaccines in the Agency for Medicinal Products and Medical Devices

H3.3. **Mikulčić D**, Pipić-Kosanović M, Truban Žulj R, Tomić S: Quality control of blood and plasma derivatives in the Agency for Medicinal Products and Medical Devices

## **14:00 – 15:00 PLENARY LECTURE (Orchid Hall)**

**PL2. Sarantopoulos C**: Neuronal potassium channels: Novel targets for analgesia and neuroprotection

**15:00 – 17:00**    **Symposium 3 (S3), Mimosa Hall**  
                         **Symposium 4 (S4), Lavender Hall**  
                         **HALMED-info-day (H4, H5), Orchid Hall**

## **S3 MOLECULAR MECHANISMS OF DISEASES AND FUTURE THERAPIES**

(*Organizer and Chairperson: Volarević S*)

S3.1. **Jansen J**: Epigenetic changes in hematological malignancies

S3.2. **Jonjić S**: Pathogenesis and immunotherapy of congenital CMV infection

S3.3. **Volarević S**, Grabušić K, Barkić M, Bursać S, Oršolić I: Ribosome and diseases

## **S4 MOLECULAR BASIS AND TREATMENT OF ALZHEIMER'S DISEASE**

(*Organizer: Mück-Šeler D; Chairpersons: Mück-Šeler D, Šalković-Petrišić M*)

S4.1. **Borovečki F**: Transcriptome analysis in neurodegenerative diseases

S4.2. **Mück-Šeler D**, Mustapić M, Presečki P, Mimica N, Folnegović Šmalc V, Pivac N: Serotonergic and catecholaminergic system in Alzheimer's disease

S4.3. **Mustapić M**, Presečki P, Mimica N, Pivac N, Folnegović Šmalc V, Mück-Šeler D: Dopamine beta-hydroxylase and inflammatory cytokines in Alzheimer's disease

S4.4. **Mubrin Z**: How to treat Alzheimer's disease

## **H4 VARIOUS THEMES** (*Moderator: Filipović Sučić A*)

H4.1. **Rajh A**, Tomić S: Electronic submission: Resources, guidelines, regulatory practice

H4.2. **Drobec M**, Tomić S: Implementation of EU telematic systems in HALMED

H4.3. **Filipović Sučić A**, Tomić S: HALMED strategy for combating counterfeit medicines

H4.4. **Vitezić D**, Lovreček D: Central ethics committee: Assessment of clinical trials in Croatia

**H5 PHARMACOVIGILANCE AND CONSUMPTION OF DRUGS** (*Moderator: Macolić – Šarinić V*)

H5.1. **Macolić-Šarinić V**: Pharmacovigilance in Croatia

H5.2. **Balažin A**, Macolić-Šarinić V, Tomić S: Pharmacovigilance in clinical trials

H5.3. **Žeželić S**, Draganić P, Macolić-Šarinić V, Tomić S: Drug consumption data mining and annual report for the year 2009 in the Republic of Croatia

**17:00 – 18:00 POSTER SESSION 1**

*Chairpersons: Šalković-Petrišić M, Dikšić M*

P1.1. **Jazvinščak Jembrek M**, Švob Štrac D: P19 neurons – a model for pharmacological studies

P1.2. **Švob Štrac D**, Jazvinščak Jembrek M, Peričić D: The differential effects of chronically administered GABA-A receptor ligands on recombinant GABA-A receptor expression

P1.3. **Vlanić J**, Jazvinščak Jembrek M, Švob Štrac D, Peričić D: The effects of zolpidem treatment and withdrawal on the *in vitro* expression of recombinant GABA<sub>A</sub> receptors expressed in HEK 293 cells

P1.4. **Filipović B**, Matak I, Bach-Rojecky L, Lacković Z: Botulinum toxin A in experimental model of migraine and/or trigeminal neuropathy

P1.5. **Matak I**, Lacković Z: Retrograde axonal transport of Botulinum toxin A in rat spinal motor neurons: An immunohistochemical study

P1.6. **Knezović A**, Marjanović AM, Osmanović-Barilar J, Riederer P, Šalković-Petrišić M: The onset of brain insulin dysfunction following the streptozotocin central application in rat

P1.7. **Osmanović Barilar J**, Plaschke K, Riederer P, Šalković-Petrišić M: Chronic corticosteron treatment affects brain insulin system in rats

P1.8. **Šalković-Petrišić M**, Kuljiš R: A new platform for characterization of the rat model of sporadic Alzheimer's disease

P1.9. **Škrget M**, Perdan-Pirkmajer K, Kržan M: The influence of levetiracetam on histamine transport into neonatal rat astrocytes

P1.10. Kovačević T, Skelin I, **Dikšić M**: Chronic fluoxetine treatment reduces dopamine and serotonin transporter densities in an OBX rat model of depression

P1.11. **Blažević S**, Dolenc P, Jurčić Ž, Hranilović D: Pharmacologically induced hyperserotonemia: Perinatal treatments of rats with 5-hydroxytryptophan and tranylecypromine

P1.12. **Nenadić-Šviglin K**, Nedić G, Nikolac M, Mustapić M, Mück-Šeler D, Pivac N: Sleep disturbances and platelet serotonin in alcoholism

P1.13. **Mršić-Pelčić J**, Pilipović K, Vujičić B, Vitezić D, Župan G: The influence of erythropoietin treatment on oxidative stress parameters in cortex of rats exposed to transient middle cerebral artery occlusion

P1.14. **Pilipović K**, Župan Ž, Župan G: Effects of enoxaparin on brain-derived neurotrophic factor and heat shock protein-70 expressions in the hippocampus following traumatic brain injury in rats

P1.15. Pilipović K, **Mladinić Pejatović M**, Mazzone G, Župan Ž, Nistri A, Župan G: Histological brain changes following traumatic brain injury in rats treated by pioglitazone: A preliminary study

*Chairpersons: Bradamante V, Rošin-Grget K*

P1.16. **Maraković J**, Orešković D, Radoš M, Vukić M, Jurjević I, Chudy D, Klarica M: Effect of osmolarity on CSF volume during ventriculo-aqueductal and ventriculo-cisternal perfusions in cats

P1.17. **Orešković D**, Klarica M: The formation of cerebrospinal fluid: Nearly a hundred years of interpretations and misinterpretations

P1.18. Bulat M, **Klarica M**: Recent insights into a new hydrodynamics of the cerebrospinal fluid

P1.19. **Macan M**, Lovrić J, Konjevoda P, Bradamante V: Do atorvastatin and pravastatin show antioxidant action?

P1.20. **Sleem AA**, Abdel-Salam OME, Shafee N: Hepatoprotective effects of cynara extract and silymarin on carbon tetrachloride-induced hepatic damage in rats

P1.21. **Pašalić I**, Čužić S, Bošnjak B, Bosnar M, Dominis Kramarić M, Marković D, Hrvacić B: Toll-like receptor 9 mediated inflammation in the mice lungs after challenge with synthetic oligodeoxynucleotides expressing immunostimulatory CpG motifs

P1.22. **Čelić T**, Kapetanović E, Španjol J, Gršković A, Bobinac D: Effect of preservation solution on kidney antioxidant capacity and injury in cold ischemia

P1.23. **Brkić D**, Alajbeg I, Telen S, Andabak A, Alajbeg A: PY Naphthalan – physical properties and chemical composition of potential remedy for epithelial tissue diseases

P1.24. **Peroš K**, Meštović S, Anić-Milošević S, Rošin-Grget K, Šlaj M: Antimicrobial effect of fluoride toothpaste on salivary *Streptococcus mutans* and *Lactobacillus spp.* in children treated with fixed orthodontic appliances

P1.25. **Badel T**, Keros J, Savić Pavčin I, Rošin-Grget K, Grbeša Đ: Bisphosphonates treatment, osteoporosis, and oral health – relationship with osteonecrosis of the jaw

P1.26. **Badel T**, Savić Pavičin I, Kern J, Šegović S, Rošin-Grget K: Tobacco use and dental caries experience in young Croatian army recruits 2000

P1.27. **Badovinac A**, Vražić D, Puhar I, Božić D, Plančak D: Use of antiseptic mouthwashes in patients referred to the periodontist

P1.28. **Šutej I**, Peroš K, Benutić A, Capak K, Rošin-Grget K: Salivary flow, pH and calcium concentration in the saliva of tobacco smokers

**18:00 – 19:00 Annual Assembly of the Croatian Pharmacological Society (Orchid Hall)**

## **SEPTEMBER 17 (FRIDAY)**

**09:00 – 10:00 PLENARY LECTURE (Orchid Hall)**

**PL3. Vanhoutte PM:** The endothelial saga

**10:30 – 12:30 Symposium 5 (S5), Mimosa Hall  
Symposium 6 (S6), Lavender Hall  
Workshop for responsible persons in pharmacovigilance: ‘What did the new Rule book bring?’ (Orchid Hall)**

**S5 EXPERIMENTAL CENTRAL NERVOUS SYSTEM DAMAGE: MECHANISMS AND THERAPY** (*Organizer: Župan G; Chairpersons: Župan G, Casamenti F*)

S5.1. **Casamenti F**, Fiorentini A, Rosi MC, Grossi C: *In vivo* modulation by lithium salts of Alzheimer's pathology and hippocampal neurogenesis in a mouse model of A $\beta$ PP deposition

S5.2. **Šalković-Petrišić M**, Osmanović-Barilar J, Knezović A, Mandel S, Youdim M, Riederer P: Therapeutic strategies in rat model of sporadic Alzheimer's disease

S5.3. **Nistri A**: Experimental spinal damage *in vitro*: Mechanisms and pharmacological neuroprotection

S5.4. Kuzhandaivel A, **Mladinić Pejatović M**, Nistri A: Molecular mechanisms underlying neuronal death after spinal cord injury

S5.5. **Župan G**, Pilipović K, Župan Ž, Mršić-Pelčić J, Frković V, Dangubić B: Pioglitazone and enoxaparin are promising novel neuroprotective drugs in the rat model of traumatic brain injury

S5.6. **Mršić-Pelčić J**, Pilipović K, Vujičić B, Vitezić D, Župan G: Erythropoietin treatment and ischemic stroke model in rats

**S6 PHARMACOLOGICAL ASPECTS OF SELECTED FUNCTIONAL FOODS AND ITS CONSTITUENTS** (*Organizer: Boban M; Chairpersons: Boban M, Medić-Šarić M*)

S6.1. **Tuberoso CIG**: Beyond food: Natural compounds and potential health benefits

S6.2. **Debeljak Ž**, Bojić M, Medić-Šarić M: Antiaggregatory activity of flavonoids

S6.3. **Boban M**: Alcoholic beverages and uric acid: Effects on vascular and biochemical indicators of oxidative stress

S6.4. **Jerković I**: Honey volatiles profiling

S6.5. **Katalinić V**, Generalić I, Skroza D, Ljubenkov I: Polyphenolic profile and biological properties of *Vitis vinifera* leaves extracts

**14:00 – 15:00 PLENARY LECTURE (Orchid Hall)**

**PL4. Li X:** The validation of protein targets for drug discovery

**15:00 – 16:00 POSTER SESSION 2**

*Chairpersons: Vitezić D, Draganić P*

- P2.1. **Radošević N**, Popović B, Vlahović-Palčevski V: Effects of educational campaign about the rational antibiotic use on public attitudes towards antibiotics
- P2.2. **Kusturica J**, Rakovac L, Mulabegović N, Kapić E, Mijanović M, Rakanović-Todić M, Kulo A: Medicine use in pregnancy – a pilot study in two cities in Bosnia and Herzegovina
- P2.3. **Ercceg D**, Rakić J, Borić I, Pivalica D, Vurdelja M, Labar B: Use of drugs and dietary supplements in Croatian athletes (from 4 team sports) selected for doping control in 2009
- P2.4. **Kučan M**, Vitezić D: ACE inhibitors drug usage in Croatia and Slovenia during the nine-year period
- P2.5. **Lekić L**, Mulabegović N, Burnazović Ristić L, Lekić A: Specificity of pharmaceutical marketing and requirements for prescription drugs' promotion in Bosnia and Herzegovina
- P2.6. Cvek J, **Balažin A**, Tomić S: Interactions between herbal medicinal products and conventional drugs
- P2.7. **Čačić L**, Peronja M, Tomić S: Influenza vaccines in Croatia – approval and quality control
- P2.8. **Šimunda-Perojević Z**, Šimpraga B, Zorić N, Tomić S: “Patient friendly“ patient information leaflet (package leaflet)
- P2.9. **Filipović Sučić A**, Ilić Martinac A, Milčić N, Tomić S, Sokolić M, Uzeirbegović S: Quality control of possible counterfeit medicines seized on the illegal market in Croatia
- P2.10. **Draganić P**, Žeželić S, Macolić-Šarinić V, Tomić S: Antibacterials for systemic use consumption in the Republic of Croatia in 2005, 2006, 2007 and 2008
- P2.11. **Lovrić M**, Božina N, Hajnšek S, Sporiš D, Lalić Z, Granić P: Effect of ABC drug transporter genotypes on antiepileptic drug disposition
- P2.12. **Nikolac M**, Hercigonja Novković V, Dodig-Ćurković K, Ćurković M, Nedić G, Mück-Šeler D, Lauc G, Pivac N: Association of attention-deficit/hyperactivity disorder symptoms with the solute carrier family (sodium/hydrogen exchanger) isoform 9 (SLC9A9)
- P2.13. **Boričević Maršanić V**, Grgić N, Juretić Z, Dodig-Ćurković K: Outpatient treatment of children and adolescents with antidepressants

*Chairpersons: Boban M, Mulabegović N*

- P2.14. **Burnazović-Ristić L**, Mulabegović N, Kučukalić A, Džubur-Kulenović A, Rakanović-Todić M, Kulo A, Bečić F, Kusturica J: Is PTSD undertreated even decade after the war in Bosnia and Herzegovina?
- P2.15. **Rakanović-Todić M**, Mulabegović N, Ibrulj S, Čatović A, Aganović-Mušinović I, Kurtović-Alajbegović A, Suljić E, Kusturica J, Burnazović-Ristić L, Kulo A: Tridecactide cytogenetic effects
- P2.16. Mulabegović N, **Burnazović-Ristić L**, Rakanović-Todić M, Kusturica J, Bečić F: Multiple sclerosis treatment – neuropeptide approach
- P2.17. **Franjić S**, Debeljak Ž, Čulig J: Therapeutic monitoring of carbamazepine and its 10,11-epoxide in epileptic patients
- P2.18. **Budimir D**, Jajić I, Mudnić I, Kozina B, Osrečak M, Boban M: Influence of ampelotechnical procedures in vineyard on vasodilatory effects of wine

- P2.19. **Jajić I**, Krnić M, Modun D, Budimir D, Gunjača G, Vuković J, Kozina B, Boban M: Acute effects of red wine, beer and vodka on plasma oxidative stress markers after oxygen administration
- P2.20. **Modun D**, Vuković J, Sutlović D, Budimir D, Boban M: Comparison of breath and blood alcohol concentrations in a controlled drinking study
- P2.21. **Boban N**, Tonkić M, Budimir D, Boban M: Association of bacterial resistance to wine and antimicrobial drugs
- P2.22. **Politeo O**, Skočibušić M, Maravić A, Ruščić M, Miloš M: Antimicrobial activity of the essential oil from dalmatian black pine (*Pinus nigra* ssp. *dalmatica*)
- P2.23. **Gunjača G**, Budimir D, Boban M: Increased arterial stiffness and central systolic blood pressure as indicators of impaired vascular function in hypercholesterolemic subjects
- P2.24. **Jovanović Ž**, Čulig J, Peršić V, Ružić A: Efficacy of orlistat in obesity pharmacotherapy: Croatian experience
- P2.25. **Turčić P**, Jurakić-Tončić R, Lipozenčić J: Lansoprasole as fatal cause of toxic epidermal necrolysis
- P2.26. **Vuljak M**: Alpha glutathione-S-transferase /Alpha-GST/ as an indicator of acute damage of hepatocytes in patients with induced hepatic microsomal enzymes
- P2.27. Lalić Z, **Miškulin M**, Dumić A: Unguent with propolis extract – new approach in conservative treatment of haemorrhoids
- P2.28. **Sameljak S**, Bošnjak Pašić M: Croatian patients attitudes toward self-reporting of adverse events
- P2.29. **Mirošević Skvrce N**, Božina N, Macolić-Šarinić V, Merćep I, Zibar L, Tomić S: SLCO1B1 variants as pharmacogenetic predisposition for adverse drug reactions induced by HMGCoA reductase inhibitors (case series)

## **SEPTEMBER 18 (SATURDAY)**

**09:00 – 11:00**    **Symposium 7 (S7), Mimosa Hall**  
**Symposium 8 (S8), Lavender Hall**  
**Workshop for responsible persons in pharmacovigilance: ‘What did the new Rule book bring?’ (Orchid Hall)**

### **S7 CLINICAL PHARMACOLOGY: FROM DRUG DEVELOPMENT TO DRUG PRESCRIBING** (*Organizer and Chairperson: Francetić I*)

- S7.1. **Likić R**: E-learning approach to the teaching of rational therapeutics to final year students at the Zagreb Medical School: Lessons and future prospects
- S7.2. **Makar-Aušperger K**, Francetić I, Erdeljić V, Likić R, Radačić Aumiler M: Pharmacogenetics in everyday practice: Warfarin dosing regimen
- S7.3. **Francetić I**: Contribution of clinical pharmacology to everyday clinical medicine

### **S8 NEPHROPHARMACOLOGY** (*Organizer: Samaržija I; Chairpersons: Samaržija I, Ljutić D*)

- S8.1. **Ljutić D**: Erythropoietin: A new treatment possibility

- S8.2. **Bubić-Filipi LJ**, Purić Z, Purić H, Granić P: Mycophenolic acid and cyclosporine in kidney transplantation. Is therapeutic drug monitoring important?
- S8.3. **Jerin L**, Trivanović D: Nephrotoxicity of the chemotherapeutic agents
- S8.4. **Samaržija I**: Changes in kidney function after glucocorticoid treatment
- S8.5. **Rački S**: Renin-angiotensin system and kidney
- S8.6. **Purić Z**, Bubić-Filipi LJ, Pasini J: Therapy with kidney transplantation in children in Croatia

**11:30 – 13:30 Symposium 9 (S9), Mimosa Hall**  
**Round table (RT), Lavender Hall**  
**Workshop for responsible persons in pharmacovigilance: ‘What did the new Rule book bring?’ (Orchid Hall)**

**S9 PHARMACOGENOMICS** (*Organizer: Božina N; Chairpersons: Božina N, Alfirević A*)

- S9.1. **Božina N**: Clinical pharmacogenomics and potential application in personalized medicine
- S9.2. **Alfirević A**: Pharmacogenetics and drug-induced hypersensitivity reactions
- S9.3. **Sertić J**, Rako I, Jakić-Razumović J, Caban D, Pleština S: K-RAS: A potential marker of prognosis and treatment efficacy in oncology
- S9.4. **Čuković-Čavka S**, Božina N, Sertić J, Vucelić B: Pharmacogenetics of thiopurine drugs and inflammatory bowel disease
- S9.5. **Bilić I**, Božina N, Pleština S, Sertić J: Dihydropyrimidine dehydrogenase (*DPYD*) gene variants and 5-Fluorouracil toxicity
- S9.6. **Mirošević Skvrce N**, Božina N, Merćep I, Zibar L, Macolić-Šarinić V, Tomić S: *SLCO1B1* variants as pharmacogenetic predisposition for myotoxicity induced by HMGC<sub>o</sub>A reductase inhibitors

**RT. COMPLIANCE: A NIGHTMARE OR A USEFUL TOOL** (*Organizer and Moderator: Frančišković T; Participants: Moro Lj, Petković M, Vlahović-Palčevski V*)

**13:30 CLOSING CEREMONY**